Compare Crispr Therapeutics AG (CRSP) vs Duolingo Inc (DUOL) Price & Performance

CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% on the day, reflecting a bearish technical trend amid weak financials. The company reported no revenue in 2025, with a net loss of $581.60M and negative profit margins, though it beat Q2 2026 EPS estimates. Analyst consensus remains bullish with a $67.83 price target, while recent news highlights upcoming clinical data readouts for its gene-editing therapies as potential catalysts.

The outlook hinges on pipeline execution, with key data expected by end-2026, but high cash burn and lack of revenue pose significant risks. Upside depends on successful clinical outcomes and commercialization of CASGEVY, while downside risks include trial failures and sustained losses.

Duolingo (DUOL) trades at $151.22, down 0.33% on the day, as the stock shows mixed technical signals with a bullish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong growth with revenue reaching $1.04 billion in 2025 and net income of $414 million, representing a robust 35.87% net margin. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $0.66 exceeding the $0.604 forecast. Analyst sentiment remains divided with a 37.5% buy rating consensus amid ongoing insider selling activity.

The outlook remains cautiously optimistic as Duolingo's AI-driven growth strategy and expanding user base support continued revenue expansion, though valuation multiples appear elevated with a P/E of 17.87 and P/S of 6.47. Key risks include CEO share liquidations, competitive pressures in edtech, and the challenge of sustaining high profit margins. The stock trades near analyst consensus targets, suggesting limited near-term upside potential from current levels.